| Ytd | -27.53% | |
| 1y | -72.35% |
| Open | 2.59 | Prev Close | 2.59 | Low | 2.56 | High | 2.63 | Mkt Cap | 239.09M |
| Vol | 1.12M | Avg Vol | 1.21M | EPS | -0.46 | P/E | N/A | Forward P/E | -17.25 |
| Beta | 0.60 | Short Ratio | 10.82 | Inst. Own | 32.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-02 | 50-d Avg | 2.89 | 200-d Avg | 4.73 | 1yr Est | 35.47 |
AVXL News
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
Multiple peer-reviewed publications point to biological link between autism spectrum disorder (ASD)
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp
US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics sur
Anavex shares fall after pulling EU filing for blarcamesine in Alzheimer's; EMA feedback prompts
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared
New study links early brain cleanup failure to Alzheimer's, supporting Anavex Life drug approach
Anavex highlighted a new peer-reviewed study published by University of California in Proceedings of
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
Anavex Life Sciences' stock rises despite no news, up over 40% this year as investors watch Alzh
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL)
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.06) per share which beat the ana
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), today announc
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-st
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
Retail investors are prepping for a lighter week of corporate earnings featuring Costco, MongoDB, Ul
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL)
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Anavex Life Sciences (NASDAQ:AVXL) w
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
Anavex reports sustained cognitive benefits from oral blarcamesine, showing slower Alzheimer's p
Anavex reports sustained cognitive benefits from oral blarcamesine, showing slower Alzheimer's p
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL)
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both mal
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL)
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabili
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL)
Anavex published data showing blarcamesine prevented amyloid-related brain damage in mice, supportin
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an